| Name | Title | Contact Details |
|---|
American Nuclear Insurers (ANI) is a joint underwriting association created by some of the largest insurance companies in the United States. Our purpose is to pool the financial assets pledged by our member companies to provide the significant amount of property and liability insurance required for nuclear power plants and related facilities throughout the world.
Arminco Inc. is the premier provider of dental design, construction, project management, and equipment sales & service. Projects are overseen by a full-service, in-house team of financial experts, designers, architects, contractors and equipment specialists. Projects include pediatric and orthodontics, surgical and other medical offices, veterinary practices as well as restaurants, churches, nail boutiques and other high end establishments. Founded in 1996, Arminco Inc. has grown from a small family business to a 50+ employee, multi-million dollar company operating throughout the US.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Price Forbes is an independent insurance broker established in 1893 and headquartered in London. As part of Ardonagh Specialty, it is recognized as a leading broker in the London market. The company has a global presence, with offices worldwide, and specializes in wholesale insurance broking, focusing on complex risk management solutions for large multinational companies. The services offered by Price Forbes include specialist insurance broking, risk management, and reinsurance solutions through its division, Price Forbes Re. This division provides tailored reinsurance broking, capital solutions, and strategic advisory services, utilizing analytics to meet client needs. Price Forbes also has a strong presence in Africa, with operations in South Africa and partnerships across sub-Saharan Africa. In addition to its business activities, Price Forbes is committed to community involvement through the Ardonagh Community Trust, supporting charitable initiatives and contributing over £1.5 million to various causes.